Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Status Not yet recruiting

Clinical Trial Summary

This study aims to investigate the safety and efficacy of radiotherapy combined with Toripalimab (PD-1 inhibitor) in the treatment of locally advanced adenocarcinoma of the gastroesophageal junction.

Clinical Trial Description

In this study, patients with locally advanced adenocarcinoma of gastroesophageal junction will be enrolled to explore the safety and efficacy of preoperative radiotherapy and chemotherapy combined with Toripalimab (PD-1). Around 45 patients will be recruited in this one-arm cohort. All patients in this cohort will be treated with preoperative radiotherapy and chemotherapy plus PD-1 for two times, then another two times of PD-1 before operation. After surgery, postoperative chemotherapy plus PD-1 will be carried out for four times. This study focuses on the safety of chemoradiotherapy combined with immunotherapy, and whether the TRG grade, LC, DFS have been improved. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04061928
Study type	Interventional
Source	Peking University
Contact	Jianhao Geng, MD
Phone	+86-18500227857
Email	gengjh3@sina.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	August 26, 2019
Completion date	August 25, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04082364` - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer	Phase 2/Phase 3
Recruiting	`NCT04931654` - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer	Phase 1/Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Recruiting	`NCT01747707` - Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer	Phase 2
Active, not recruiting	`NCT03221426` - Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)	Phase 3
Completed	`NCT02178956` - A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer	Phase 3
Active, not recruiting	`NCT02872116` - Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	Phase 3
Completed	`NCT02538562` - Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea	N/A
Recruiting	`NCT05322577` - A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.	Phase 1
Terminated	`NCT01813253` - Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer	Phase 3
Recruiting	`NCT06346392` - AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2	Phase 3
Recruiting	`NCT06250894` - Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction	Phase 2
Active, not recruiting	`NCT04276493` - Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab	Phase 1/Phase 2
Terminated	`NCT02726399` - Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer	Phase 2
Recruiting	`NCT05395780` - A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer	Phase 2
Completed	`NCT02661971` - FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)	Phase 2/Phase 3
Completed	`NCT02581462` - FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer	Phase 2/Phase 3
Completed	`NCT00917462` - Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer	Phase 2
Recruiting	`NCT05187182` - CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer	Phase 1
Not yet recruiting	`NCT06411171` - Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:	Phase 3